<DOC>
	<DOCNO>NCT02116543</DOCNO>
	<brief_summary>This proof concept study design evaluate safety , tolerability , pharmacokinetics , antiviral activity TD-6450 treatment naïve subject GT-1 , GT-2 GT-3 chronic HCV .</brief_summary>
	<brief_title>TD-6450 MAD Study HCV Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Subject HCV antibody positive Subject treatment naïve , history exposure ( single multiple dose ) interferon , ribavirin direct act antiviral . Subject liver biopsy within 3 year Fibroscan evaluation within 6 month prior Screening clearly excludes cirrhosis . If available prior Screening , absence cirrhosis must confirm prior subject enrollment use either Fibroscan Fibrosure® . Subject negative hepatitis A ( HAV ) , hepatitis B ( HBV ) , human immunodeficiency virus ( HIV ) . Subject prior histological evidence cirrhosis current clinical evidence cirrhosis opinion investigator . Subject history evidence nonhepatitis C chronic liver disease . Subject estimate creatinine clearance &lt; 80 ml/min 1860 year age , inclusive ; &lt; 70 ml/min &gt; 60 year age , calculate use CockcroftGault equation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
</DOC>